Ingrid Zhang, Chief Commercial Officer at Legend Biotech, shared by Legend Biotech, on LinkedIn, added:
”It’s a privilege to join Legend Biotech at such an important moment for the company, and honestly, for me too. This one feels personal. During the search process, I met a lot of people across the organization, and what struck me wasn’t the pitch. It was how often the same thing came up in conversation: a real, deep commitment to patients living with multiple myeloma. Hearing that again and again is what made the decision easy.
I’m especially grateful to Alan Bash for his leadership through this transition, and I’m genuinely looking forward to working closely with him as President, CARVYKTI.
Thank you to the Board for their confidence, and to everyone who’s already made me feel so welcome. I can’t wait to meet more of you in the weeks ahead.”
Quoting Legend Biotech:
”Today, we announced the appointment of Ingrid Zhang as Chief Executive Officer of Legend Biotech. Ingrid is an accomplished global biopharmaceutical executive with deep experience leading commercial organizations, driving business growth and advancing innovative medicines.
Under Ingrid’s leadership, we will continue to build on our strong foundation, advance our pipeline, expand our impact and execute on our long-term growth strategy as we work to transform outcomes for patients through cell therapy. We also thank Alan Bash for his strong leadership during the CEO transition period and look forward to his continued partnership as President, CARVYKTI. Read today’s announcement”
Read more articles about Legend Biotech on OncoDaily.